Oculis Holding AG announced on February 14, 2025, the pricing of an oversubscribed underwritten offering of 5,000,000 of its ordinary shares at a price of $20.00 per share. This offering is expected to generate total gross proceeds of $100 million, before deducting underwriting discounts, commissions, and offering expenses.
The offering is anticipated to close on or about February 18, 2025, subject to customary closing conditions. The new shares will be issued from the company’s existing capital band, increasing the total number of registered shares authorized by its Articles of Association to 53,943,700.
Oculis intends to utilize the net proceeds from this offering to advance and accelerate its clinical development pipeline, with a particular focus on its novel neuroprotective clinical candidate, Privosegtor (OCS-05). The funds will also be allocated for working capital and general corporate purposes, providing significant financial support for the company's ongoing operations and strategic initiatives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.